Filing Details

Accession Number:
0001144204-18-034653
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-06-18 18:14:59
Reporting Period:
2018-06-14
Accepted Time:
2018-06-18 18:14:59
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1175151 Cytosorbents Corp CTSO Surgical & Medical Instruments & Apparatus (3841) 980373793
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1368151 Vincent Capponi C/O Cytosorbents Corporation
7 Deer Park Drive, Suite K
Monmouth Junction NJ 08852
Chief Operating Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-06-14 11,367 $3.75 319,350 No 4 M Direct
Common Stock Acquisiton 2018-06-15 8,633 $3.75 327,983 No 4 M Direct
Common Stock Acquisiton 2018-06-15 40,000 $0.88 367,983 No 4 M Direct
Common Stock Disposition 2018-06-14 11,367 $12.00 356,616 No 4 S Direct
Common Stock Disposition 2018-06-15 8,633 $12.00 347,983 No 4 S Direct
Common Stock Disposition 2018-06-15 15,215 $12.35 332,768 No 4 F Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 F Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2018-06-14 11,367 $0.00 11,367 $3.45
Common Stock Stock Option (Right to Buy) Disposition 2018-06-15 8,633 $0.00 8,633 $3.45
Common Stock Stock Option (Right to Buy) Disposition 2018-06-15 40,000 $0.00 40,000 $0.88
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
69,933 2010-05-05 2020-05-05 No 4 M Direct
61,300 2010-05-05 2020-05-05 No 4 M Direct
0 2011-06-25 2018-06-25 No 4 M Direct
Footnotes
  1. Stock option exercise and open market sale conducted pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
  2. Includes (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company: (a) 17,900 RSUs granted on February 24, 2017, (b) 54,000 RSUs granted on June 7, 2016, (c) 125,000 RSUs granted on April 8, 2015 and (d) 10,100 RSUs granted on March 15, 2018 and reported on this Form 4, (ii) the following RSUs subject to vesting as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting: (a) 11,980 of the RSUs granted to the reporting person on February 24, 2017 and unvested as of the date hereof, and (b) 25,334 RSUs granted on February 28, 2018 and unvested as of the date hereof and (iii) 88,454 shares of common stock owned by the reporting person.
  3. These stock options vested at the discretion of the Company's Board of Directors based on satisfying certain criteria including a timely completion of the sepsis trial, raising capital for the Company, and partnering and business development. The options did not vest on May 5, 2010.